argenx SE (ARGX) Stock Forecast, Price Target & Predictions
ARGX Stock Forecast
argenx SE stock forecast is as follows: an average price target of $446.55 (represents a -17.00% downside from ARGX’s last price of $538.01) and a rating consensus of 'Buy', based on 19 wall street analysts offering a 1-year stock forecast.
ARGX Price Target
The average price target for argenx SE (ARGX) is $446.55 based on 1-year price targets from 19 Wall Street analysts in the past 3 months, with a price target range of $546.00 to $326.27. This represents a potential -17.00% downside from ARGX's last price of $538.01.
ARGX Analyst Ratings
According to 19 Wall Street analysts, argenx SE's rating consensus is 'Buy'. The analyst rating breakdown for ARGX stock is 1 'Strong Buy' (5.26%), 16 'Buy' (84.21%), 2 'Hold' (10.53%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
argenx SE Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 29, 2024 | Joel Beatty | Robert W. Baird | $515.00 | $495.92 | 3.85% | -4.28% |
| Jul 26, 2024 | Douglas Tsao | H.C. Wainwright | $533.00 | $492.06 | 8.32% | -0.93% |
| Jul 23, 2024 | Leland Gershell | Oppenheimer | $546.00 | $461.01 | 18.44% | 1.49% |
| Jul 22, 2024 | Joon Lee | Truist Financial | $540.00 | $461.01 | 17.13% | 0.37% |
| Jul 12, 2024 | Gavin Clark-Gartner | Evercore ISI | $533.00 | $461.72 | 15.44% | -0.93% |
| Jun 26, 2024 | Douglas Tsao | H.C. Wainwright | $490.00 | $451.55 | 8.52% | -8.92% |
| Jun 24, 2024 | Joon Lee | Truist Financial | $480.00 | $441.15 | 8.81% | -10.78% |
| Jun 24, 2024 | George Farmer | Scotiabank | $416.00 | $437.96 | -5.01% | -22.68% |
| Jun 24, 2024 | Derek Archila | Wells Fargo | $542.00 | $394.47 | 37.40% | 0.74% |
| Jun 24, 2024 | Alex Thompson | Stifel Nicolaus | $500.00 | $436.79 | 14.47% | -7.06% |
The latest argenx SE stock forecast, released on Jul 29, 2024 by Joel Beatty from Robert W. Baird, set a price target of $515.00, which represents a 3.85% increase from the stock price at the time of the forecast ($495.92), and a -4.28% decrease from ARGX last price ($538.01).
argenx SE Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 10 | 12 |
| Avg Price Target | - | $509.50 | $502.33 |
| Last Closing Price | $538.01 | $538.01 | $538.01 |
| Upside/Downside | -100.00% | -5.30% | -6.63% |
In the current month, the average price target of argenx SE stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to argenx SE's last price of $538.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 29, 2024 | UBS | Neutral | Neutral | Hold |
| Aug 23, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 06, 2024 | Barclays | Equal-Weight | Overweight | Upgrade |
| Jul 29, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 26, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jul 26, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 26, 2024 | Guggenheim | Buy | Buy | Hold |
| Jul 26, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 25, 2024 | Deutsche Bank | - | Buy | Upgrade |
| Jul 23, 2024 | Oppenheimer | - | Outperform | Upgrade |
argenx SE's last stock rating was published by UBS on Aug 29, 2024. The company gave ARGX a "Neutral" rating, the same as its previous rate.
argenx SE Financial Forecast
argenx SE Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $219.14M | $174.16M | $137.98M | $75.19M |
| Avg Forecast | $538.91M | $494.40M | $409.26M | $376.23M | $346.95M | $292.61M | $256.55M | $22.24M | $15.01M | $10.54M | $286.01M |
| High Forecast | $622.19M | $551.12M | $463.17M | $425.79M | $354.65M | $331.15M | $307.86M | $26.68M | $18.01M | $12.64M | $343.21M |
| Low Forecast | $466.94M | $470.11M | $354.81M | $326.18M | $316.34M | $253.68M | $205.24M | $17.79M | $12.00M | $8.43M | $228.81M |
| # Analysts | 17 | 14 | 7 | 6 | 12 | 9 | 16 | 16 | 15 | 13 | 18 |
| Surprise % | - | - | - | - | - | - | - | 9.85% | 11.61% | 13.10% | 0.26% |
argenx SE's average Quarter revenue forecast for Jun 23 based on 16 analysts is $256.55M, with a low forecast of $205.24M, and a high forecast of $307.86M. ARGX's average Quarter revenue forecast represents a 17.07% increase compared to the company's last Quarter revenue of $219.14M (Mar 23).
argenx SE EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 14 | 7 | 6 | 12 | 9 | 16 | 16 | 15 | 13 | 18 |
| EBITDA | - | - | - | - | - | - | - | $-87.16M | $-100.51M | $-200.63M | $-169.63M |
| Avg Forecast | $-407.49M | $-373.84M | $-309.46M | $-205.90M | $-262.34M | $-221.26M | $196.34M | $-217.62M | $-61.43M | $-96.28M | $218.88M |
| High Forecast | $-353.07M | $-355.47M | $-268.29M | $-164.72M | $-239.20M | $-191.82M | $235.60M | $-174.10M | $-49.15M | $-77.02M | $262.66M |
| Low Forecast | $-470.46M | $-416.72M | $-350.22M | $-247.08M | $-268.16M | $-250.40M | $157.07M | $-261.15M | $-73.72M | $-115.54M | $175.11M |
| Surprise % | - | - | - | - | - | - | - | 0.40% | 1.64% | 2.08% | -0.77% |
undefined analysts predict ARGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than argenx SE's previous annual EBITDA (undefined) of $NaN.
argenx SE Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 14 | 7 | 6 | 12 | 9 | 16 | 16 | 15 | 13 | 18 |
| Net Income | - | - | - | - | - | - | - | $-28.87M | $-38.61M | $-235.04M | $-208.75M |
| Avg Forecast | - | $4.30M | $-49.81M | $-204.16M | $-66.95M | $-78.70M | $193.26M | $-215.79M | $-61.74M | $-96.56M | $215.45M |
| High Forecast | - | $39.26M | $-41.20M | $-163.33M | $-34.84M | $-65.08M | $231.91M | $-172.63M | $-49.39M | $-77.25M | $258.54M |
| Low Forecast | - | $-14.52M | $-58.34M | $-245.00M | $-141.53M | $-92.17M | $154.61M | $-258.95M | $-74.08M | $-115.87M | $172.36M |
| Surprise % | - | - | - | - | - | - | - | 0.13% | 0.63% | 2.43% | -0.97% |
argenx SE's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ARGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
argenx SE SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 14 | 7 | 6 | 12 | 9 | 16 | 16 | 15 | 13 | 18 |
| SG&A | - | - | - | - | - | - | - | $149.17M | $135.29M | $108.18M | $126.58M |
| Avg Forecast | $794.64M | $729.01M | $603.47M | $90.64M | $511.59M | $431.47M | $136.82M | $32.79M | $22.13M | $15.54M | $152.53M |
| High Forecast | $917.44M | $812.64M | $682.95M | $108.77M | $522.94M | $488.30M | $164.19M | $39.35M | $26.55M | $18.64M | $183.04M |
| Low Forecast | $688.52M | $693.19M | $523.18M | $72.51M | $466.46M | $374.06M | $109.46M | $26.23M | $17.70M | $12.43M | $122.03M |
| Surprise % | - | - | - | - | - | - | - | 4.55% | 6.11% | 6.96% | 0.83% |
argenx SE's average Quarter SG&A projection for Jun 23 is $136.82M, based on 16 Wall Street analysts, with a range of $109.46M to $164.19M. The forecast indicates a -8.28% fall compared to ARGX last annual SG&A of $149.17M (Mar 23).
argenx SE EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 17 | 14 | 7 | 6 | 12 | 9 | 16 | 16 | 15 | 13 | 18 |
| EPS | - | - | - | - | - | - | - | $-0.52 | $-0.70 | $-4.26 | $-4.01 |
| Avg Forecast | - | $0.07 | $-0.84 | $-0.72 | $-1.13 | $-1.32 | $1.09 | $1.31 | $1.78 | $1.30 | $1.10 |
| High Forecast | - | $0.66 | $-0.69 | $-0.59 | $-0.59 | $-1.10 | $1.25 | $1.54 | $2.03 | $1.52 | $1.17 |
| Low Forecast | - | $-0.24 | $-0.98 | $-0.84 | $-2.38 | $-1.55 | $1.00 | $1.09 | $1.63 | $1.08 | $1.05 |
| Surprise % | - | - | - | - | - | - | - | -0.40% | -0.39% | -3.27% | -3.63% |
According to undefined Wall Street analysts, argenx SE's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ARGX previous annual EPS of $NaN (undefined).
argenx SE Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ZLAB | Zai Lab | $20.51 | $101.00 | 392.44% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BGNE | BeiGene | $198.49 | $247.75 | 24.82% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| ARGX | argenx SE | $538.01 | $446.55 | -17.00% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
ARGX Forecast FAQ
Is argenx SE a good buy?
Yes, according to 19 Wall Street analysts, argenx SE (ARGX) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 16 'Buy' recommendations, accounting for 89.47% of ARGX's total ratings.
What is ARGX's price target?
argenx SE (ARGX) average price target is $446.55 with a range of $326.27 to $546, implying a -17.00% from its last price of $538.01. The data is based on 19 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will argenx SE stock go up soon?
According to Wall Street analysts' prediction for ARGX stock, the company can go down by -17.00% (from the last price of $538.01 to the average price target of $446.55), up by 1.49% based on the highest stock price target, and down by -39.36% based on the lowest stock price target.
Can argenx SE stock reach $800?
ARGX's average twelve months analyst stock price target of $446.55 does not support the claim that argenx SE can reach $800 in the near future.
What are argenx SE's analysts' financial forecasts?
argenx SE's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $918.35M (high $1.02B, low $793.05M), average EBITDA is $-505M (high $-370M, low $-623M), average net income is $-168M (high $-40.644M, low $-338M), average SG&A $1.11B (high $1.21B, low $976.21M), and average EPS is $-0.0448 (high $1.11, low $-1.844). ARGX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.82B (high $2.06B, low $1.62B), average EBITDA is $-1.297B (high $-1.142B, low $-1.484B), average net income is $-250M (high $-165M, low $-318M), average SG&A $2.22B (high $2.52B, low $1.98B), and average EPS is $-1.484 (high $-0.626, low $-2.067).
Did the ARGX's actual financial results beat the analysts' financial forecasts?
Based on argenx SE's last annual report (Dec 2022), the company's revenue was $410.75M, beating the average analysts forecast of $311.55M by 31.84%. Apple's EBITDA was $-693M, missing the average prediction of $61.17M by -1232.42%. The company's net income was $-710M, missing the average estimation of $57.15M by -1341.55%. Apple's SG&A was $472.13M, beating the average forecast of $190.19M by 148.24%. Lastly, the company's EPS was $-13.05, missing the average prediction of $4.18 by -412.12%. In terms of the last quarterly report (Mar 2023), argenx SE's revenue was $219.14M, beating the average analysts' forecast of $22.24M by 885.46%. The company's EBITDA was $-87.155M, missing the average prediction of $-218M by -59.95%. argenx SE's net income was $-28.871M, missing the average estimation of $-216M by -86.62%. The company's SG&A was $149.17M, beating the average forecast of $32.79M by 354.94%. Lastly, the company's EPS was $-0.52, missing the average prediction of $1.31 by -139.57%